Global Biosimulation Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Biosimulation Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

  • Healthcare
  • Upcoming Report
  • Oct 2024
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Biosimulation Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2024 –2031
Diagram Market Size (Base Year)
USD 1.57 Billion
Diagram Market Size (Forecast Year)
USD 8.84 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Certara
  • Simulations Plus
  • Dassault Systèmes
  • Schrödinger
  • ACD/Labs

Global Biosimulation Market Segmentation, By Product and Service (Software, Molecular Simulation, In House, Contract Services), Application (Drug Development, Drug Discovery, Other Applications), Delivery Model (Subscription Models, Ownership Models), End User (Biotech, Pharma Companies, Contract Research Organizations (CROs), Regulatory Authorities, Other End Users) – Industry Trends and Forecast to 2031.

Biosimulation Market

Biosimulation Market Analysis

Developing a new drug requires a significant amount of research and resources. Every stage of the drug development process, from clinical trials to approval, has a very high failure rate. Bio simulation can significantly reduce these chances. Biosimulation not only helps predict the chances of a drug failing during the development process but also lowers the cost of any other possible failures by reducing the number of clinical experiments.

Biosimulation Market Size

Global biosimulation market size was valued at USD 1.57 billion in 2023 and is projected to reach USD 8.84 billion by 2031, with a CAGR of 24.1% during the forecast period of 2024 to 2031.

Report Scope and Market Segmentation       

Attributes

Biosimulation Key Market Insights

Segmentation

  • By Product and Service: Software, Molecular Simulation, In House, Contract Services
  • By Application: Drug Development, Drug Discovery, Other Applications
  • By Delivery Model: Subscription Models, Ownership Models
  • By End User: Biotech, Pharma Companies, Contract Research Organizations (CROs), Regulatory Authorities, Other End Users

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Key Market Players

Certara (U.S.), Simulations Plus (U.S.), Dassault Systèmes (France), Schrödinger, Inc (U.S.), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (U.K.), Evidera (U.S.), In silico biosciences (U.S.), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (U.S.), Nuventra Pharma (U.S.)

Market Opportunities

  • High demand for expanded care delivery
  • The expanding applications and increased use of personalized medicine
  • Surge in healthcare expenditure, advancements in healthcare infrastructure

Biosimulation Market Definition

Biosimulation is a mathematical simulation of a biological procedure that employs computer-aided programmes to simulate biological processes and systems. Model-based drug development refers to the ability to make data-driven decisions using a quantitative framework at all stages of drug development. Biosimulation is a promising technology that is used specifically in pharmaceutical research to improve the drug discovery and development cycle.

Biosimulation Market Dynamics

Drivers

  • The rise in the adoption of biosimulation software

The increase in R&D investments in the pharmaceutical and biotechnology industries, as well as the increased adoption of biosimulation software by regulatory bodies and technologically advanced QSP systems, are expected to drive the biosimulation market growth during the forecast period.

  • The reduction in development costs and growth of biologics

The demands to reduce drug discovery and development costs, as well as the growth of the biologics and biosimilar markets, are expected to fuel the growth of the biosimulation market.

  • Government investments for healthcare interoperability

The federal government's increased funding to drive the adoption of these solutions has further influenced the market. Furthermore, the increase in healthcare spending, advancements in healthcare infrastructure, and a high demand for expanded care delivery all benefit the biosimulation market.

Opportunities

The expanding applications and increased use of personalised medicine and biosimulation solutions for paediatric drug development will provide additional opportunities for the biosimulation market to grow in the coming years.

Restraints/Challenges

The lack of standardisation is also expected to stifle growth in the biosimulation market over the forecast period. The difficulty in matching the complexity of biological systems and processes and the scarcity of biosimulation and modelling experts may pose additional challenges to the biosimulation market's growth in the near future.

This biosimulation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biosimulation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on Biosimulation Market

The COVID-19 pandemic had a significant impact on the healthcare industry, including the biosimulation market. The need to test and develop COVID-19 vaccine candidates quickly fueled demand for biosimulation software and services.

Biosimulation Market Scope

The biosimulation market is segmented on the basis of product and service, application, delivery model and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Service

  • Software
    • Lecular Modeling and Simulation Software
    • Pbpk Modeling and Simulation Software
    • Pk/Pd Modeling and Simulation Software
    • Trial Design Software
    • Toxicity Prediction Software
    • Other Biosimulation Software
  • Molecular simulation
  • In house
  • Contract services
    • In-house Services
    • Contract services

Application

  • Drug development
  • Drug discovery
  • Other application

Delivery model

  • Subscription model
  • Ownership model

End User

  • Biotech
  • Healthcare Payers
  • Regulatory authorities
  • Contract research organizations

Biosimulation Market Regional Analysis

The biosimulation market is analysed and market size insights and trends are provided by country, product and service, application, delivery model and end user as referenced above.

The countries covered in the biosimulation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Due to the general increasing number of collaborations between key players to improve drug discovery capabilities, North America dominates the biosimulation market. Furthermore, the use of in-silico models during regulatory policy enforcement to ensure high patient safety and treatment standards will drive the region's biosimulation market growth during the forecast period. The Asia Pacific biosimulation market is expected to grow significantly due to a growing preference for contract research organisations and rising healthcare I.T. expenditure. Furthermore, consistent improvements in healthcare infrastructure and increased research and development activities in developing countries are expected to drive the growth of the biosimulation market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Biosimulation Market Share Analysis

The biosimulation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to biosimulation market.

Biosimulation Market Leaders Operating in the Market Are:

  • Certara (U.S.)
  • Simulations Plus (U.S.)
  • Dassault Systèmes (France)
  • Schrödinger, Inc (U.S.)
  • ACD/Labs (Canada)
  • Chemical Computing Group (Canada)
  • Physiomics (U.K.)
  • Evidera (U.S.)
  • In silico biosciences (U.S.)
  • INOSIM Software (Germany)
  • Insilico Biotechnology (Germany)
  • LeadInvent Technologies (India)
  • Rosa (U.S.)
  • Nuventra Pharma (U.S.)

Latest Developments in Biosimulation Market

  • Advanced Chemistry Development will release new updates for its Percepta and Spectrus platform applications in September 2020. This expanded the company's product offerings by including new features like NMR and M.S. functionality for data analysis and 3D optimization in the chromatography lineup.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Segmentation, By Product and Service (Software, Molecular Simulation, In House, Contract Services), Application (Drug Development, Drug Discovery, Other Applications), Delivery Model (Subscription Models, Ownership Models), End User (Biotech, Pharma Companies, Contract Research Organizations (CROs), Regulatory Authorities, Other End Users) – Industry Trends and Forecast to 2031. .
The Global Biosimulation Market size was valued at USD 1.57 USD Billion in 2023.
The Global Biosimulation Market is projected to grow at a CAGR of 24.1% during the forecast period of 2024 to 2031.
The major players operating in the market include Certara, Simulations Plus, Dassault Systèmes, Schrödinger , ACD/Labs, Chemical Computing Group, Physiomics, Evidera, In silico biosciences, INOSIM Software, Insilico Biotechnology, LeadInvent Technologies, Rosa, Nuventra Pharma,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.